Better Therapeutics- Tradeable Rights - March 2021 Total Liabilities

The latest total liabilities for MCADR is $21M as of September 2023. That compares with $21M in the prior-year period — down 1.5% year over year. Investors often review this figure alongside Better Therapeutics- Tradeable Rights - March 2021's historical trend and sector peers before judging valuation or financial health.

Over the past year, MCADR's total liabilities moved from $21M to $21M — a 1.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics- Tradeable Rights - March 2021's operating scale or balance-sheet position.

A total liabilities figure of $21M for MCADR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MCADR's total liabilities ($21M), review year-over-year change from $21M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.